The collection require sponsors of any
drug, biologic or device marketing application to certify to the
absence of clinical investigators and/or disclose those financial
interests as required, when covered clinical studies are submitted
to FDA in support of product marketing.
The estimated number of
respondents has increased from 902 to 1,000 for Certification, from
90 to 100 for Disclosure, and from 902 to 1,000 for Recordkeeping
due to an increase in the estimated number of affected
applications. The estimated number of respondents for third-party
disclosure has decreased from 10,554 to 7,106. The sum of these
adjustments has resulted in a 414-hour decrease of the total hour
burden. No program changes were made.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.